Edaravone Mitsubishi-Tokyo.
Mitsubishi-Tokyo (formerly Mitsubishi Chemical) is developing edaravone (norphenazone), a free radical scavenger, for the potential treatment of cardiovascular disease, cerebrovascular ischemia and cerebral edema. By February 2000, edaravone had been filed in Japan for the treatment of acute brain infarction, and was in phase III trials for subarachnoid hemorrhage [365460]. The compound blocks the action of the lipoperoxide, 15-HPETE, which normally increases with age and may be associated with neurodegeneration.
Memorial University of Newfoundland, Faculty of Medicine, Basic Medical Sciences, Health Sciences Centre, St John's, NF, A1B 3V6, Canada. rtabrizc@morgan.ucs.mun.ca
R
R
Tabrizchi
D000983:Antipyrine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D000075202:Contraindications; D015507:Drugs, Investigational / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans
D015507:Drugs, Investigational; D016166:Free Radical Scavengers; D000077553:Edaravone; D000983:Antipyrine